PMV Pharmaceuticals计划2027年第一季度为铂类耐药/难治性卵巢癌提交Rezatapopt新药申请

美股速递
Sep 10

PMV Pharmaceuticals Inc宣布,公司计划在2027年第一季度向监管机构提交其候选药物Rezatapopt的新药申请(NDA),该药物用于治疗铂类耐药或难治性卵巢癌患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10